the new uspto rules and their impact on biomedical patent prosecution mojdeh bahar, j.d.,m.a....
Post on 25-Dec-2015
220 Views
Preview:
TRANSCRIPT
The New USPTO Rules and their The New USPTO Rules and their Impact on Biomedical Patent Impact on Biomedical Patent ProsecutionProsecution
Mojdeh Bahar, J.D.,M.A.Mojdeh Bahar, J.D.,M.A.Technology Licensing SpecialistTechnology Licensing SpecialistOffice of Technology TransferOffice of Technology TransferNational Institutes of HealthNational Institutes of HealthU.S. Department of Health & Human ServicesU.S. Department of Health & Human Services
FLC MAR Annual MeetingOctober 2007
22
Road MapRoad Map
NIH’s MissionNIH’s Mission NIH’s Patent Prosecution PolicyNIH’s Patent Prosecution Policy NIH’s Typical Patent Prosecution StrategyNIH’s Typical Patent Prosecution Strategy Very Brief Description of the New Rules Very Brief Description of the New Rules Possible ImpactsPossible Impacts Change in Prosecution StrategyChange in Prosecution Strategy
33
NIH’s MissionNIH’s Mission
To uncover new knowledge To uncover new knowledge that will lead to improved that will lead to improved
public healthpublic health
44
NIH’s Patent Prosecution NIH’s Patent Prosecution PolicyPolicySeek patent protection if:Seek patent protection if: facilitates availability of the technology for preventive, diagnostic, facilitates availability of the technology for preventive, diagnostic,
therapeutic, or other commercial usetherapeutic, or other commercial use further research and development is necessary to realize the further research and development is necessary to realize the
technology’s primary usetechnology’s primary use commercial or public health value of the technology warrants the commercial or public health value of the technology warrants the
expenditure of fundsexpenditure of funds research has a practical utility or a reasonable expectation of future research has a practical utility or a reasonable expectation of future
practical utilitypractical utility
Do Do notnot seek patent protection if: seek patent protection if: Commercialization and technology transfer can best be accomplished Commercialization and technology transfer can best be accomplished
without patent protectionwithout patent protection
55
NIH’s Typical Patent NIH’s Typical Patent Prosecution StrategyProsecution Strategy Provisional Patent ApplicationProvisional Patent Application Initial Stage Foreign Filing (PCT Initial Stage Foreign Filing (PCT
Application)Application) National Stage Foreign FilingNational Stage Foreign Filing
– Includes U.S. Patent Application (non-Includes U.S. Patent Application (non-provisional)provisional)
Country validation or registrationCountry validation or registration– EPO ValidationEPO Validation
66
NIH Typical Patent NIH Typical Patent Prosecution TimelineProsecution Timeline
1.1. Provisional Patent Application FiledProvisional Patent Application Filed2.2. 12 Months Later: Initial Stage Foreign 12 Months Later: Initial Stage Foreign
Filing (PCT)Filing (PCT)3.3. 18 months after PCT filing (30 months 18 months after PCT filing (30 months
after the filing of the provisional after the filing of the provisional application): National Stage Foreign and application): National Stage Foreign and US National Patent ApplicationUS National Patent Application
4.4. EPO Validation and RegistrationEPO Validation and Registration
77
Types of ApplicationsTypes of Applications
CONCON– Continuation ApplicationContinuation Application
RCERCE– Request for Continued ExaminationRequest for Continued Examination
CIPCIP– Continuation in PartContinuation in Part
DIVDIVDivisional ApplicationDivisional Application
88
A Typical A Typical Pharmaceutical/Biotech Pharmaceutical/Biotech ApplicationApplication Has more than 25 claimsHas more than 25 claims Will be subject to a restriction requirement Will be subject to a restriction requirement
necessitating the filing of one or more divisional necessitating the filing of one or more divisional applicationsapplications
Will have more than one CON, CIP or RCE for Will have more than one CON, CIP or RCE for each original or divisional application.each original or divisional application.
Has Markush claims (alternative embodiments of Has Markush claims (alternative embodiments of the invention)the invention)
They are generally filed at an earlier stage when They are generally filed at an earlier stage when compared to other arts, e.g., mechanical arts.compared to other arts, e.g., mechanical arts.
99
Very Brief Description of the Very Brief Description of the New RulesNew Rules Applicants are limited to two continuations and Applicants are limited to two continuations and
one RCE as a matter of right.one RCE as a matter of right. Each application will be limited to five (5) Each application will be limited to five (5)
independent claims and twenty five (25) total independent claims and twenty five (25) total claims.claims.
Applicants need to disclose cases in which there Applicants need to disclose cases in which there are the same assignee, one common inventor, are the same assignee, one common inventor, and the applications have been filed within two and the applications have been filed within two months of one another. (except if present months of one another. (except if present application was filed before November 1, 2007).application was filed before November 1, 2007).
1010
Possible ImpactsPossible Impacts
The ability to use continuation practice to obtain the proper scope of The ability to use continuation practice to obtain the proper scope of protection necessary for commercial embodiments of early stage inventions protection necessary for commercial embodiments of early stage inventions will be limited.will be limited.a) analysis of applications and an understanding of the underlying a) analysis of applications and an understanding of the underlying technology will be more involvedtechnology will be more involvedb) decision points will be shiftedb) decision points will be shifted
Claim construction has become more important.Claim construction has become more important.
Thorough knowledge of restriction practice is now paramount.Thorough knowledge of restriction practice is now paramount. Compliance with these rules for entities with large patent portfolios is a Compliance with these rules for entities with large patent portfolios is a
daunting task.daunting task. The Markush Rules (proposed, but not yet finalized) further complicate The Markush Rules (proposed, but not yet finalized) further complicate
matters.matters. There are many unknowns in these rules: required showing for filing There are many unknowns in these rules: required showing for filing
additional continuations, impact on the overall cost of prosecution, additional continuations, impact on the overall cost of prosecution, applicant submissions and prosecution estoppel, etc.applicant submissions and prosecution estoppel, etc.
1111
Changes in Prosecution Changes in Prosecution StrategyStrategy More interactions with the inventors at the More interactions with the inventors at the
beginning of the patenting process.beginning of the patenting process. Exploring all possible directions that the Exploring all possible directions that the
research may take, in which the inventor is research may take, in which the inventor is interested.interested.
Conducting marketing campaigns in the first Conducting marketing campaigns in the first thirty months of an invention’s life.thirty months of an invention’s life.
Having the prosecution strategy more closely Having the prosecution strategy more closely follow the scientific development. follow the scientific development.
1212
OTT/NIH ContactsOTT/NIH Contacts
NIHNIH http://www.nih.govhttp://www.nih.gov
OTTOTT http://www.ott.nih.govhttp://www.ott.nih.gov
Science. Ideas. Breakthroughs.
1313
Any Questions?Any Questions?
Thank you for your kind attentionThank you for your kind attention
top related